Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: 9wald9 who wrote (878)	3/20/2002 7:26:50 PM
From: SemiBull	Read Replies (1) \| Respond to of 1139

Eli Lilly Achieves Milestone In Internet-Based Study INDIANAPOLIS -(Dow Jones)- Eli Lilly and Co . (LLY) completed the last patient visit for its first interactive clinical trial, a phase III study that assessed the safety and efficacy of Lilly ICOS's Cialis compound for erectile dysfunction. In a press release Wednesday, Eli Lilly said it is "very pleased" with the conduct of the Internet-based study, referred to as "Magellan." The study was designed with 1747 Inc., a San Francisco company that was one the e.Lilly venture fund's early investments. Lilly ICOS is Eli Lilly's joint venture with ICOS Corp. (ICOS). "The interactive technology of this trial exceeded our expectations, and we are moving forward with plans to apply this methodology to other clinical trials," Lilly ICOS said. Eli Lilly said using the Internet for study's can help ensure quality of data from the investigator and patients, reduce costs and help increase speed at which clinical data are made available to the company. Magellan's processes include real-time monitoring of patients' safety; gathering informed consent electronically; electronic tracking and shipping of the study drug; online patient history, efficacy surveys, patient diaries and feedback; and creation of a safety-monitoring role. Eli Lilly will submit the findings of the study to the U.S. Food and Drug Administration. -Carrie Kocik; Dow Jones Newswires; 201-938-5388